ATE533783T1 - Potente und selektive mittlersubstanzen von cholesterolefflux - Google Patents

Potente und selektive mittlersubstanzen von cholesterolefflux

Info

Publication number
ATE533783T1
ATE533783T1 AT07874411T AT07874411T ATE533783T1 AT E533783 T1 ATE533783 T1 AT E533783T1 AT 07874411 T AT07874411 T AT 07874411T AT 07874411 T AT07874411 T AT 07874411T AT E533783 T1 ATE533783 T1 AT E533783T1
Authority
AT
Austria
Prior art keywords
cholesterolefflux
potent
polypeptides
apo
parallels
Prior art date
Application number
AT07874411T
Other languages
German (de)
English (en)
Inventor
John K Bielicki
Jan Johansson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE533783T1 publication Critical patent/ATE533783T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07874411T 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux ATE533783T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
ATE533783T1 true ATE533783T1 (de) 2011-12-15

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07874411T ATE533783T1 (de) 2006-12-13 2007-12-13 Potente und selektive mittlersubstanzen von cholesterolefflux

Country Status (10)

Country Link
US (1) US8987192B2 (enExample)
EP (1) EP2121746B1 (enExample)
JP (1) JP2010513311A (enExample)
CN (1) CN101675072A (enExample)
AT (1) ATE533783T1 (enExample)
AU (1) AU2007349237B2 (enExample)
CA (1) CA2672131C (enExample)
DK (1) DK2121746T3 (enExample)
ES (1) ES2377329T3 (enExample)
WO (1) WO2008115303A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011101536A (ru) 2008-06-18 2012-07-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) Усовершенствованные пептидные медиаторы оттока холестерина
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
US11091529B2 (en) * 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CA2405870A1 (en) * 2000-04-06 2001-10-18 Kos Pharmaceuticals, Inc. Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7691965B2 (en) 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
BRPI0513402A (pt) 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Also Published As

Publication number Publication date
AU2007349237B2 (en) 2014-01-23
EP2121746A2 (en) 2009-11-25
ES2377329T3 (es) 2012-03-26
CA2672131C (en) 2016-06-07
HK1138292A1 (en) 2010-08-20
WO2008115303A2 (en) 2008-09-25
WO2008115303A3 (en) 2008-12-24
CA2672131A1 (en) 2008-09-25
US8987192B2 (en) 2015-03-24
US20120329703A1 (en) 2012-12-27
EP2121746B1 (en) 2011-11-16
DK2121746T3 (da) 2012-03-05
CN101675072A (zh) 2010-03-17
JP2010513311A (ja) 2010-04-30
AU2007349237A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2009155366A3 (en) Improved peptide mediators of cholesterol efflux
ATE533783T1 (de) Potente und selektive mittlersubstanzen von cholesterolefflux
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
NO20080246L (no) Anti-IGF1R-antistofformuleringer
WO2005095457A3 (en) Immunoglobulins
WO2007135571A3 (en) Blood group antigens of different types for diagnostic and therapeutic applications
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NO20082699L (no) Immunoglobuliner
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2008045406A3 (en) COMPOUNDS, SCREENINGS, AND METHODS OF TREATMENT
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
BRPI0518559A2 (pt) motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
EP4556067A3 (en) Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
TW200615399A (en) Coating material for coating platinum material, platinum material having such coating material, and glass making apparatus
NO20065252L (no) Behandling av forstyrrelser
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
WO2006022955A3 (en) Topoisomerase inhibitors
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2007111982A3 (en) Methods for treating cognitive and other disorders
CA2902209C (en) REDUCED TOXICITY PEPTIDES STIMULATING CHOLESTEROL OUTFLOW
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2004111089A3 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof